BeiGene Return on Investment 2014-2024 | ONC
Current and historical return on investment (ROI) values for BeiGene (ONC) over the last 10 years.
| BeiGene ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-09-30 |
$-0.87B |
$3.62B |
-24.11% |
| 2024-06-30 |
$-0.89B |
$3.55B |
-23.93% |
| 2024-03-31 |
$-1.10B |
$3.56B |
-28.77% |
| 2023-12-31 |
$-1.21B |
$3.74B |
-30.07% |
| 2023-09-30 |
$-1.29B |
$3.97B |
-30.55% |
| 2023-06-30 |
$-1.60B |
$4.01B |
-35.84% |
| 2023-03-31 |
$-1.72B |
$4.36B |
-35.57% |
| 2022-12-31 |
$-1.79B |
$4.59B |
-34.03% |
| 2022-09-30 |
$-1.89B |
$4.86B |
-33.23% |
| 2022-06-30 |
$-1.92B |
$5.49B |
-35.70% |
| 2022-03-31 |
$-1.95B |
$6.09B |
-39.47% |
| 2021-12-31 |
$-1.44B |
$6.34B |
-32.17% |
| 2021-09-30 |
$-1.35B |
$3.56B |
-34.64% |
| 2021-06-30 |
$-1.33B |
$3.80B |
-32.24% |
| 2021-03-31 |
$-1.21B |
$4.20B |
-31.26% |
| 2020-12-31 |
$-1.66B |
$4.05B |
-46.04% |
| 2020-09-30 |
$-1.56B |
$4.45B |
-53.96% |
| 2020-06-30 |
$-1.43B |
$2.84B |
-66.10% |
| 2020-03-31 |
$-1.16B |
$3.07B |
-60.70% |
| 2019-12-31 |
$-0.96B |
$1.22B |
-59.69% |
| 2019-09-30 |
$-0.85B |
$1.55B |
-47.67% |
| 2019-06-30 |
$-0.69B |
$1.81B |
-35.58% |
| 2019-03-31 |
$-0.77B |
$1.86B |
-41.59% |
| 2018-12-31 |
$-0.71B |
$1.94B |
-39.98% |
| 2018-09-30 |
$-0.53B |
$2.17B |
-35.50% |
| 2018-06-30 |
$-0.26B |
$1.43B |
-22.36% |
| 2018-03-31 |
$-0.16B |
$1.52B |
-17.08% |
| 2017-12-31 |
$-0.10B |
$0.84B |
-15.82% |
| 2017-09-30 |
$-0.03B |
$0.91B |
-6.30% |
| 2017-06-30 |
$-0.18B |
$0.42B |
-54.94% |
| 2017-03-31 |
$-0.15B |
$0.33B |
-52.60% |
| 2016-12-31 |
$-0.12B |
$0.37B |
-44.32% |
| 2016-09-30 |
$-0.11B |
$0.21B |
-55.28% |
| 2016-03-31 |
$-0.05B |
$0.25B |
-48.62% |
| 2015-12-31 |
$-0.04B |
$0.08B |
-91.98% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
